Evidence map›Paper›PMID 29675417›Full record

ArticleFrontiers in cardiovascular medicine2018

Developing a Reliable Mouse Model for Cancer Therapy-Induced Cardiovascular Toxicity in Cancer Patients and Survivors.

Kyung Ae Ko, Yin Wang, Sivareddy Kotla, Yuka Fujii, Hang Thi Vu, Bhanu P Venkatesulu, Tamlyn N Thomas, Jan L Medina, Young Jin Gi, Megumi Hada and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Radiation-Induced Macrovessel/Microvessel Disease.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Biomarkers of radiation-induced vascular injury.Cancer reports (Hoboken, N.J.) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Kyung Ae KoDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Yin WangDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Sivareddy KotlaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Yuka FujiiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Hang Thi VuDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Bhanu P VenkatesuluDepartment of Radiology Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Tamlyn N ThomasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jan L MedinaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Young Jin GiDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Megumi HadaTexas A&M Chancellor Research Initiative, Prairie View A&M University, Prairie View, TX, United States.
Jane Grande-AllenDepartment of Bioengineering, Rice University, Houston, TX, United States.
Zarana S PatelKBRwyle, Science and Space, Technology and Engineering, Houston, TX, United States.
Sarah A MilgromDepartment of Radiology Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Sunil KrishnanDepartment of Radiology Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Keigi FujiwaraDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jun-Ichi AbeDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
The University of Texas MD Anderson Cancer Center · USPrairie View A&M University · USRice University · USWyle (United States) · US

Funding

PAR 13-233 cART accelerates vascular aging in HIV infected subjectsR01HL123346 · NHLBI · UNIVERSITY OF ROCHESTER · PI ABE, JUN-ICHI, MAGGIRWAR, SANJAY B. · 2014 to 2018
$3.7M
p90RSK-ERK5 module, efferocytosis, and vulnerable plaque formationR01HL118462 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ABE, JUN-ICHI · 2014 to 2018
$2.0M
NHLBI NIH HHS R01 HL118462NHLBI NIH HHS R01 HL123346
6 · The paper itself

Abstract

backgroundThe high incidence of cardiovascular events in cancer survivors has long been noted, but the mechanistic insights of cardiovascular toxicity of cancer treatments, especially for vessel diseases, remain unclear. It is well known that atherosclerotic plaque formation begins in the area exposed to disturbed blood flow, but the relationship between cancer therapy and disturbed flow in regulating plaque formation has not been well studied. Therefore, we had two goals for this study; (1) Generate an affordable, reliable, and reproducible mouse model to recapitulate the cancer therapy-induced cardiovascular events in cancer survivors, and (2) Establish a mouse model to investigate the interplay between disturbed flow and various cancer therapies in the process of atherosclerotic plaque formation. METHODS AND

resultsWe examined the effects of two cancer drugs and ionizing radiation (IR) on disturbed blood flow-induced plaque formation using a mouse carotid artery partial ligation (PCL) model of atherosclerosis. We found that doxorubicin and cisplatin, which are commonly used anti-cancer drugs, had no effect on plaque formation in partially ligated carotid arteries. Similarly, PCL-induced plaque formation was not affected in mice that received IR (2 Gy) and PCL surgery performed one week later. In contrast, when PCL surgery was performed 26 days after IR treatment, not only the atherosclerotic plaque formation but also the necrotic core formation was significantly enhanced. Lastly, we found a significant increase in p90RSK phosphorylation in the plaques from the IR-treated group compared to those from the non-IR treated group.

conclusionsOur results demonstrate that IR not only increases atherosclerotic events but also vulnerable plaque formation. These increases were a somewhat delayed effect of IR as they were observed in mice with PCL surgery performed 26 days, but not 10 days, after IR exposure. A proper animal model must be developed to study how to minimize the cardiovascular toxicity due to cancer treatment.

Indexed as

atherosclerosisCancer treatment-related cardiovascular toxicitydisturbed blood flowionizing radiationp90RSK

Identifiers

PMID29675417
PMCPMC5896304
OpenAlexW2794075784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.